Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey
- PMID: 23416328
- PMCID: PMC4197011
- DOI: 10.1016/j.cgh.2013.02.011
Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey
Abstract
Background & aims: A genome-wide association study associated 5 genetic variants with hepatic steatosis (identified by computerized tomography) in individuals of European ancestry. We investigated whether these variants were associated with measures of hepatic steatosis (HS) in non-Hispanic white (NHW), non-Hispanic black, and Mexican American (MA) participants in the US population-based National Health and Nutrition Examination Survey III, phase 2.
Methods: We analyzed data from 4804 adults (1825 NHW, 1442 non-Hispanic black, and 1537 MA; 51.7% women; mean age at examination, 42.5 y); the weighted prevalence of HS was 37.3%. We investigated whether ultrasound-measured HS, with and without increased levels of alanine aminotransferase (ALT), or level of ALT alone, was associated with rs738409 (patatin-like phospholipase domain-containing protein 3 [PNPLA3]), rs2228603 (neurocan [NCAN]), rs12137855 (lysophospholipase-like 1), rs780094 (glucokinase regulatory protein [GCKR]), and rs4240624 (protein phosphatase 1, regulatory subunit 3b [PPP1R3B]) using regression modeling in an additive genetic model, controlling for age, age-squared, sex, and alcohol consumption.
Results: The G allele of rs738409 (PNPLA3) and the T allele of rs780094 (GCKR) were associated with HS with a high level of ALT (odds ratio [OR], 1.36; P = .01; and OR, 1.30; P = .03, respectively). The A allele of rs4240624 (PPP1R3B) and the T allele of rs2228603 (NCAN) were associated with HS (OR, 1.28; P = .03; and OR, 1.40; P = .04, respectively). Variants of PNPLA3 and NCAN were associated with ALT level among all 3 ancestries. Some single-nucleotide polymorphisms were associated with particular races or ethnicities: variants in PNPLA3, NCAN, GCKR, and PPP1R3B were associated with NHW and variants in PNPLA3 were associated with MA. No variants were associated with NHB.
Conclusions: We used data from the National Health and Nutrition Examination Survey III to validate the association between rs738409 (PNPLA3), rs780094 (GCKR), and rs4240624 (PPP1R3B) with HS, with or without increased levels of ALT, among 3 different ancestries. Some, but not all, associations between variants in NCAN, lysophospholipase-like 1, GCKR, and PPP1R3B with HS (with and without increased ALT level) were significant within subpopulations.
Keywords: ALT; AST; Candidate Gene Study; EAF; GCKR; Genome-wide Association Study; HDL-c; HS; LYPLAL1; MA; Mexican American; NAFLD; NASH; NCAN; NHANES III; NHB; NHW; Nonalcoholic Fatty Liver Disease; OR; PNPLA3; PPP1R3B; Replication; SNP; Third National Health and Nutrition Examination Survey; alanine aminotransferase; aspartate aminotransferase; effect allele frequency; glucokinase regulatory protein; hepatic steatosis; high-density lipoprotein cholesterol; lysophospholipase-like 1; neurocan; non-Hispanic black; non-Hispanic white; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; odds ratios; patatin-like phospholipase domain-containing protein 3; protein phosphatase 1, regulatory subunit 3b; single-nucleotide polymorphisms.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures
Comment in
-
Common genetic variants and nonalcoholic Fatty liver disease.Clin Gastroenterol Hepatol. 2013 Sep;11(9):1191-3. doi: 10.1016/j.cgh.2013.05.013. Epub 2013 May 21. Clin Gastroenterol Hepatol. 2013. PMID: 23707460 No abstract available.
Similar articles
-
Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals.Am J Clin Nutr. 2014 Apr;99(4):869-74. doi: 10.3945/ajcn.113.079749. Epub 2014 Jan 29. Am J Clin Nutr. 2014. PMID: 24477042 Clinical Trial.
-
Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.Mol Biol Rep. 2016 Dec;43(12):1359-1369. doi: 10.1007/s11033-016-4058-z. Epub 2016 Oct 17. Mol Biol Rep. 2016. PMID: 27752939 Free PMC article.
-
Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent.Hepatology. 2013 Sep;58(3):966-75. doi: 10.1002/hep.26440. Epub 2013 Jul 16. Hepatology. 2013. PMID: 23564467 Free PMC article.
-
The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.J Clin Exp Hepatol. 2015 Jun;5(2):147-58. doi: 10.1016/j.jceh.2015.02.002. Epub 2015 Feb 16. J Clin Exp Hepatol. 2015. PMID: 26155043 Free PMC article. Review.
-
Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis.Sci Rep. 2015 Mar 20;5:9284. doi: 10.1038/srep09284. Sci Rep. 2015. PMID: 25791171 Free PMC article. Review.
Cited by
-
SUGP1 is a novel regulator of cholesterol metabolism.Hum Mol Genet. 2016 Jul 15;25(14):3106-3116. doi: 10.1093/hmg/ddw151. Epub 2016 May 20. Hum Mol Genet. 2016. PMID: 27206982 Free PMC article.
-
Propensity for Intra-abdominal and Hepatic Adiposity Varies Among Ethnic Groups.Gastroenterology. 2019 Mar;156(4):966-975.e10. doi: 10.1053/j.gastro.2018.11.021. Epub 2018 Nov 13. Gastroenterology. 2019. PMID: 30445012 Free PMC article.
-
Fatty liver diseases, mechanisms, and potential therapeutic plant medicines.Chin J Nat Med. 2020 Mar;18(3):161-168. doi: 10.1016/S1875-5364(20)30017-0. Chin J Nat Med. 2020. PMID: 32245585 Free PMC article. Review.
-
The association between flavonoids intake and hypertension in U.S. adults: A cross-sectional study from The National Health and Nutrition Examination Survey.J Clin Hypertens (Greenwich). 2024 May;26(5):573-583. doi: 10.1111/jch.14807. Epub 2024 Apr 17. J Clin Hypertens (Greenwich). 2024. PMID: 38630898 Free PMC article.
-
Proteome-wide Mendelian randomization identifies potential therapeutic _targets for nonalcoholic fatty liver diseases.Sci Rep. 2024 May 23;14(1):11814. doi: 10.1038/s41598-024-62742-4. Sci Rep. 2024. PMID: 38782984 Free PMC article.
References
-
- Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303:235–241. - PubMed
-
- Adams LA, Waters OR, Knuiman MW, et al. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104:861–867. - PubMed
-
- American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1702–1704. - PubMed
-
- Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231. - PubMed
-
- Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA. 2003;289:3000–3004. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous